Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Deborah Collyar: What's In It for Patients?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement




Jul
22
Today In Oncology
Can Consolidative Thoracic Radiotherapy Improve Outcomes During Immunotherapy Maintenance in Extensive-Stage SCLC?
Early Research Examines Daraxonrasib in NRAS-Mutant Melanoma
Treatment Delays May Increase Metastasis Risk in Nonmetastatic Colorectal Cancer
Integrating Environmental Health Into Pediatric Cancer Care May Improve Outcomes
Emergency Department Cancer Diagnosis Associated With Higher Mortality Across 16 Cancer Types
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo